Commercial/Healthcare Exchange Step Criteria

Effective: January 1, 2020

Step Therapy Name: Ophthalmic NSAIDs

Step 1 Agent(s): Ilevro, BromSite, Prolensa

Step2 Agent(s): Nevanac, Acuvail

Medication/Class Description: The ophthalmic NSAIDs are indicated for the management of ocular pain and inflammation in the postoperative setting. Ketorolac 0.5% ophthalmic solution is also indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Of the currently available ophthalmic NSAIDs used in an outpatient setting, Nevanac and Ilevro are unique in that they are the only NSAID prodrug formulations. Nepafenac, the active ingredient in Nevanac and Ilevro, is converted to the primary active NSAID agent, amfenac, by ocular tissue hydrolases after nepafenac penetration of the cornea. The clinical significance of this is not known at this time. Bromfenac 0.009% ophthalmic solution, Ilevro, and Prolensa are dosed once daily (QD); the other agents are dosed two times daily (Acuvail), three time daily (Nevanac), or four times daily (ketorolac 0.4%, ketorolac 0.5%, and diclofenac 1%). Ilevro and Nevanac are ophthalmic suspensions and must be shaken well before use.

Required Medical Information:

1. Previous therapies tried/failed

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Exceptions for Stepped Medications

1. Patient has had a trial and failure of Ilevro, BromSite, OR Prolensa, defined as:
    a. Failure to improve symptoms; **OR**
2. Patient has an intolerance or contraindication to Ilevro, BromSite, OR Prolensa, defined as (but not limited to):
    a. Allergic reaction**;**
    b. Adverse drug reactions.

References:

1. Product Information: ILEVRO(TM) ophthalmic suspension, nepafenac 0.3% ophthalmic suspension. Alcon Laboratories, Inc. (per Manufacturer), Fort Worth, TX, 2014.
2. Product Information: NEVANAC(R) topical ophthalmic suspension, nepafenac 0.1% topical ophthalmic suspension. Alcon Laboratories, Inc. (per FDA), Fort Worth, TX, 2011.

Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/21/2019
2	Update	Moved Prolensa to a step 1 agent Removed double step to a trial and failure of ONE step 1 agent	Step 1 Agent(s) Exceptions for Stepped Medications	10/01/2021

Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.